GlobeNewswire: Sonoma Pharmaceuticals, Inc. Contains the last 10 of 220 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T18:38:57ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/02/27/1992316/0/en/Sonoma-Pharmaceuticals-Announces-Asset-Purchase-Agreement-with-Middle-East-Partner-MicroSafe-Group.html?f=22&fvtc=4&fvtv=12352Sonoma Pharmaceuticals Announces Asset Purchase Agreement with Middle East Partner MicroSafe Group2020-02-27T22:00:00Z<![CDATA[PETALUMA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin and wound conditions, is pleased to announce that it successfully closed on an asset purchase agreement for certain wound care, disinfection and animal health care products in the Middle East, Australia and Europe for $1.1 million with MicroSafe Group.]]>https://www.globenewswire.com/news-release/2020/02/14/1985512/0/en/Sonoma-Pharmaceuticals-Reports-Third-Quarter-FY-2020-Financial-Results.html?f=22&fvtc=4&fvtv=12352Sonoma Pharmaceuticals Reports Third Quarter FY 2020 Financial Results2020-02-14T22:30:00Z<![CDATA[PETALUMA, Calif., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin conditions, today announced financial results for the third quarter and nine months ended December 31, 2019.]]>https://www.globenewswire.com/news-release/2020/01/23/1974612/0/en/Sonoma-Pharmaceuticals-Engages-Maxim-Group-LLC-to-Explore-Strategic-Opportunities-for-its-U-S-Dermatology-Division.html?f=22&fvtc=4&fvtv=12352Sonoma Pharmaceuticals Engages Maxim Group LLC to Explore Strategic Opportunities for its U.S. Dermatology Division2020-01-23T21:43:42Z<![CDATA[PETALUMA, Calif., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin conditions, today announced that it has commenced a process to explore and evaluate strategic alternatives for its U.S. Dermatology Division and has engaged Maxim Group LLC as its financial advisor to assist in this process. The Company does not have a defined timeline for such a transaction and cannot provide any assurance whether or when any transaction will be announced or consummated.]]>https://www.globenewswire.com/news-release/2019/11/29/1954219/0/en/Sonoma-Pharmaceuticals-Announces-Closing-of-1-6-Million-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=12352Sonoma Pharmaceuticals Announces Closing of $1.6 Million Public Offering of Common Stock2019-11-29T21:42:40Z<![CDATA[PETALUMA, Calif., Nov. 29, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the closing of a public offering of 446,577 shares of common stock at a public offering price of $3.50 per share.]]>https://www.globenewswire.com/news-release/2019/11/26/1952756/0/en/Sonoma-Pharmaceuticals-Announces-Pricing-of-Approximately-1-6-million-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=12352Sonoma Pharmaceuticals Announces Pricing of Approximately $1.6 million Public Offering of Common Stock2019-11-26T15:10:25Z<![CDATA[PETALUMA, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the pricing of its previously announced “best efforts” public offering of shares of its common stock at a public offering price of $3.50 per share, with anticipated gross proceeds of $1.6 million, before deducting placement agent fees and offering expense payable by the Company. The offering is expected to close on or about November 29, 2019, subject to regulatory approval and customary closing conditions.]]>https://www.globenewswire.com/news-release/2019/11/26/1952332/0/en/Sonoma-Pharmaceuticals-Announces-Proposed-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=12352Sonoma Pharmaceuticals Announces Proposed Public Offering of Common Stock2019-11-26T00:54:32Z<![CDATA[PETALUMA, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the launch of a “best efforts” public offering of shares of its common stock.]]>https://www.globenewswire.com/news-release/2019/11/14/1947686/0/en/Sonoma-Pharmaceuticals-Reports-Second-Quarter-FY-2020-Financial-Results.html?f=22&fvtc=4&fvtv=12352Sonoma Pharmaceuticals Reports Second Quarter FY 2020 Financial Results2019-11-14T23:00:00Z<![CDATA[PETALUMA, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin conditions, yesterday announced financial results for the second quarter and six months ended September 30, 2019.]]>https://www.globenewswire.com/news-release/2019/10/01/1923736/0/en/Sonoma-Pharmaceuticals-Announces-Management-Changes.html?f=22&fvtc=4&fvtv=12352Sonoma Pharmaceuticals Announces Management Changes 2019-10-01T21:09:14Z<![CDATA[Agreement with CEO and Interim CFO Bubba Sandford endsAmy Trombly Appointed as Interim CEO John Dal Poggetto Appointed as New CFO]]>https://www.globenewswire.com/news-release/2019/08/13/1901442/0/en/Sonoma-Pharmaceuticals-Reports-First-Quarter-FY-2020-Financial-Results.html?f=22&fvtc=4&fvtv=12352Sonoma Pharmaceuticals Reports First Quarter FY 2020 Financial Results2019-08-13T21:35:00Z<![CDATA[Strong Quarter-Over-Quarter Performance]]>https://www.globenewswire.com/news-release/2019/07/12/1881998/0/en/Sonoma-Pharmaceuticals-Regains-Compliance-with-Nasdaq-Minimum-Bid-Price-Rule.html?f=22&fvtc=4&fvtv=12352Sonoma Pharmaceuticals Regains Compliance with Nasdaq® Minimum Bid Price Rule2019-07-12T13:00:00Z<![CDATA[PETALUMA, Calif., July 12, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin conditions, today announced that it received a formal determination letter from Nasdaq notifying the company that it is now compliant with the minimum bid price requirement for continued listing on the Nasdaq Capital Market® and is no longer subject to delisting at this time.]]>